Description: MiCo BioMed Co., Ltd. provides on-site diagnostic systems based on Lab-on-a-Chip technology. The company offers molecular diagnostics devices comprising Veri-Q PREP M16 (G2-16TU) system, a device that include membrane to extract nucleic acid using tube; VERI-Q PCR 316, a device to get the result in a short time using plastic chip; VERI-Q PCR 204 (G2-4), a device to deliver the real-time PCR system; PCR and sample prep kits; Veri-Q PCR 316 PB products; and LabChip, sample tube, and pre-filtering column products. It also provides biological chemistry products, including VERI-Q Multi, a cholesterol diagnostic product; VERI-Q Hb Mate and VERI-Q RED, a hemoglobin monitoring system; and VERI-Q PRO, a blood glucose monitoring system. In addition, the company offers immunodiagnostics products comprising VERI-Q COVID-19 Ag Rapid Test and VERI-Q COVID-19 IgGIgM Rapid Test for COVID testing; VERI-Q PinoView, a device for detecting markers of specific diseases through antigen-antibody reaction; and Opti96 ELISA plate/Kit. The company was formerly known as MiCo NanoBioSys Co., Ltd. and changed its name to MiCo BioMed Co., Ltd. in March 2018. MiCo BioMed Co., Ltd. was founded in 2009 and is headquartered in Seongnam-si, South Korea.
Home Page: www.micobiomed.com
54 Changeop-ro
Seongnam-si,
13449
South Korea
Phone:
82 1 661 6555
Officers
| Name | Title |
|---|---|
| Mr. Young Seok Hong | Chief Executive Officer |
Exchange: KQ
Country: KR : Korea (Republic of)
Currency: Korean Won (₩)
| GIC Sector: | Energy |
|---|---|
| GIC Group: | Energy |
| GIC Industry: | Oil, Gas & Consumable Fuels |
| GIC Sub-Industry: | Coal & Consumable Fuels |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.5342 |
| Price-to-Sales TTM: | 10.3614 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 75 |